Insider holders · CIK 0002093101
Atrium Therapeutics, Inc. · RNA
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| Sarah BoyceDirector | 138,668 | — | 138,668 | Sep 22, 2026 · 4:20 pm EDT | Form 4 |
| Kathleen P. GallagherSee Remarks | 119,729 | — | 119,729 | Sep 22, 2026 · 4:17 pm EDT | Form 4 |
| Steven George HughesChief Medical Officer | 51,638 | — | 51,638 | Sep 22, 2026 · 4:23 pm EDT | Form 4 |
| Husam YounisChief Scientific Officer | 41,441 | — | 41,441 | Sep 22, 2026 · 4:24 pm EDT | Form 4 |
| Rocio Martin HoyosChief Strategy Officer | 38,340 | — | 38,340 | Sep 22, 2026 · 4:15 pm EDT | Form 4 |
| Brendan R. WinslowChief Financial Officer | 36,859 | — | 36,859 | Sep 22, 2026 · 4:17 pm EDT | Form 4 |
| Stephanie KenneySee Remarks | 33,085 | — | 33,085 | Sep 22, 2026 · 4:18 pm EDT | Form 4 |
| W. Michael FlanaganDirector | 31,974 | — | 31,974 | Sep 22, 2026 · 4:20 pm EDT | Form 4 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.